In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Lei Lei Wu

News Reporter

Seven months after dropping some very limited, but promising, data on three patients who received its gamma delta T cell treatment for leukemia, IN8bio revealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

In glimpse of tiny pa­tient group, IN8bio’s ‘off-the-shelf’ gam­ma delta T cells re­main durable

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

In glimpse of tiny patient group, IN8bio’s ‘off-the-shelf’ gamma delta T cells remain durable

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development